Alpha Emitter Market to Grow with a CAGR of 9.80% through 2028
Advancement in
radiopharmaceuticals and Increase in the incidence of cancer is expected to
drive the Global Alpha Emitter Market growth in the forecast period, 2024-2028.
According to
TechSci Research report, “Alpha Emitter Market – Global Industry Size,
Share, Trends, Competition Forecast & Opportunities, 2028”, the
Global Alpha Emitter Market stood at USD 466.10 billion in 2022 and is
anticipated to grow with a CAGR of 9.80% in the forecast period, 2024-2028. The
awareness among individuals regarding Alpha Emitter has led to favorable market
conditions for the global Alpha Emitter market. Several factors contribute to
the growth of various Alpha Emitter products.
The Global Alpha
Emitter Market is experiencing a significant boost due to the increasing demand
for nuclear medicine. Alpha emitters, such as radium-223 and actinium-225, are
crucial in targeted alpha-particle cancer therapy. As awareness of the
effectiveness and precision of alpha emitters in treating various types of
cancer spreads, the demand for these radioactive isotopes is on the rise. This
driver is further propelled by advancements in medical research and the
development of innovative alpha-emitting radiopharmaceuticals.
The expansion of
nuclear power plants and the need for precise measurements drive demand. Alpha
emitters are used for reactor maintenance, fuel analysis, and radiation
monitoring within these facilities. Alpha emitters play a role in environmental
monitoring to measure air and water quality. As environmental regulations
become stricter, industries must employ these isotopes for compliance, which
will further fuel market growth.
In July 2021,
Alpha Tau's Alpha DaRT™, designed for precise tumor destruction using potent
alpha radiation while sparing healthy tissue, has earned FDA's Breakthrough
Device Designation for treating Squamous Cell Carcinoma of the skin and oral
cavity without a curative standard of care. Furthermore, preclinical studies
support its evaluation in various cancer indications, including skin, pancreas,
breast, and GBM. The transaction implies a pro forma equity value of
approximately USD1 billion and is anticipated to yield gross proceeds of up to
USD367 million. This includes funds from the trust account of Healthcare
Capital Corp. (Nasdaq: HCCC), totaling up to USD275 million, along with a USD92
million PIPE investment.
The construction
and expansion of nuclear reactors worldwide requires a steady supply of
alpha-emitting isotopes. This steady demand supports the growth of the alpha
emitter market.
In today's
fast-paced world, alpha emitters play a crucial role in precision medicine.
They can be used to target and treat specific diseases, such as cancer, with
minimal damage to healthy tissue. This precision allows for faster recovery
times and reduced side effects for patients. Alpha emitter-based therapies are
gaining prominence in cancer treatment. They deliver high-energy alpha
particles directly to cancer cells, destroying them more effectively than
traditional treatments. This can lead to faster remission and improved patient
outcomes. In the industrial sector, alpha emitters are used for non-destructive
testing, ensuring the quality and safety of products at a faster pace. They are
also employed in oil well logging and environmental monitoring, allowing for
quicker and more accurate data collection. Alpha emitters are essential in
nuclear energy production. They contribute to the generation of electricity in
nuclear power plants, providing a reliable and sustainable source of energy to
meet the fast-growing demands of our world. Alpha emitters are critical in
scientific research, helping researchers study nuclear properties and
reactions. Their use accelerates the pace of discoveries in fields such as
nuclear physics and chemistry.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Alpha Emitter Market.”
The growing use
of alpha emitters in radiopharmaceuticals. Alpha-emitting isotopes, such as
radium-223 and actinium-225, are finding applications beyond cancer treatment.
They are being incorporated into diagnostic and therapeutic
radiopharmaceuticals for conditions like bone metastases and arthritis. The versatility
of alpha emitters in radiopharmaceuticals arises from their ability to target
specific tissues and deliver high-energy alpha particles. This precision is
valuable in diagnosing and treating diseases that involve specific organ
systems or tissues.
In recent times,
Alpha emitter-based targeted alpha-particle therapy is revolutionizing cancer
treatment. Recent advancements have made it possible to use alpha emitters to
precisely target and destroy cancer cells while sparing healthy tissue. This
approach is proving effective in treating various types of cancer, offering
hope to patients with limited treatment options. Alpha emitters are at the
forefront of precision medicine. Recent developments in radiopharmaceuticals,
such as alpha-emitting isotopes linked to tumor-targeting molecules, enable
tailored treatments based on a patient's specific cancer type and genetic
profile. This personalized approach enhances treatment outcomes. However, the Limited
Availability of Source Materials may hinder market growth. Moreover, challenges
related to Public Perception and Safety Concerns may pose obstacles to the Alpha
Emitters market in the near future.
The Global Alpha
Emitter Market is segmented into Type of Radionuclide, medical application, country
distribution, and company.
Based on its type
of radionuclide, the Actinium-225 is highly attractive due to its radioactive
decay characteristics. It decays with the emission of alpha particles, making
it an effective tool for targeted alpha-particle therapy. The high-energy alpha
particles released during decay have a short range in tissue, delivering a
concentrated and lethal dose of radiation to cancer cells. The effectiveness of
Actinium-225 in killing cancer cells with minimal damage to surrounding healthy
tissues makes it a preferred choice for alpha-emitting radiopharmaceuticals.
This selectivity reduces side effects and enhances the safety and efficacy of
cancer treatments, leading to its dominance in the market. Actinium-225 has
demonstrated versatility in its applications within cancer therapy. It can be
conjugated to various targeting molecules, such as antibodies or peptides,
enabling the creation of highly specific radiopharmaceuticals that can target a
wide range of cancer types. This versatility allows Actinium-225 to address a
broader spectrum of cancers, including hematological malignancies (e.g.,
leukemia and lymphoma) and solid tumors (e.g., prostate and breast cancer). The
ability to tailor treatments to different cancer types increases its demand and
market dominance. Actinium-225 has shown promising clinical results in
early-stage trials and research studies.
Based on region,
North America segment is expected to grow during the forecast
period. the United States and Canada, boasts advanced healthcare
infrastructure and well-established research facilities. This infrastructure
supports the development and adoption of alpha emitter-based therapies,
contributing to market dominance. The availability of state-of-the-art medical
facilities and research institutions facilitates clinical trials, research, and
the integration of alpha emitters into healthcare practices. North America has
a thriving pharmaceutical industry with a strong focus on innovative therapies,
including alpha emitter-based radiopharmaceuticals. Pharmaceutical companies in
the region invest significantly in research and development, clinical trials,
and the commercialization of alpha emitters. Their commitment to innovation
drives market leadership. Regulatory agencies like the U.S. Food and Drug
Administration (FDA) and Health Canada have been proactive in evaluating and
approving alpha emitter-based therapies. Regulatory approvals instill
confidence in healthcare providers, leading to greater adoption of these
therapies. North America's streamlined regulatory processes contribute to its
dominant market position.
The Asia-Pacific
market is poised to be the fastest-growing market, offering lucrative growth
opportunities for Alpha Emitter players during the forecast period. Factors
such as countries like China, India, and Japan, has been witnessing substantial
growth in its healthcare sector. The increasing middle-class population and
expanding healthcare infrastructure are driving demand for advanced medical
treatments. As healthcare access improves and awareness of innovative therapies
grows, there is a significant potential for alpha emitter-based treatments to
gain traction in the Asia-Pacific market. The Asia-Pacific region is experiencing
a rising burden of cancer cases, including ovarian, prostate, and bone cancers.
This increase in cancer incidence creates a strong demand for effective
treatment options. Alpha emitter-based therapies, known for their precision in
targeting cancer cells, are well-suited to address the specific needs of cancer
patients in the region. Governments in countries like China and Japan are
investing in healthcare research and fostering collaboration between academia,
industry, and healthcare providers.
Major companies
operating in Global Alpha Emitter Market are:
- Actinium Pharmaceutical Inc.
- Alpha Tau Medical Ltd
- Bayer AG
- Fusion Pharmaceuticals
- IBA Radiopharma Solutions
- RadioMedix Inc.
- Telix Pharmaceuticals Ltd
Download Free Sample Report
Customers can also
request for 10% free customization on this report.
“The Advancements
in Radiation Therapy and increasing Precise Cancer Therapy Solutions are key
drivers of the Alpha Emitter market. In recent years, The rising incidence of
cancer globally necessitates innovative treatment options, boosting the
adoption of alpha emitters in oncology. Alpha emitters are crucial in
monitoring air and water quality for radiation pollutants, enhancing
environmental safety. Moreover, the growing consumer emphasis on preventative
healthcare products has enhanced production and marketing efforts. To meet the
demands of the market, manufacturers are increasingly incorporating
cutting-edge technologies with high production efficiency. Rising consumer
acceptance and continuous product innovation will further ensure the growth of
the Alpha Emitters and supplements market in the coming years.,” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“Alpha Emitter
Market – Global Industry Size, Share, Trends, Opportunity, & Forecast
2018-2028 Segmented By Type of Radionuclide (Astatine (At-211), Radium
(Ra-223), Actinium (Ac-225), Lead (Pb-212), Bismuth (Bi-212), Other), By
Medical Application (Prostate Cancer, Bone Metastasis, Ovarian Cancer,
Pancreatic Cancer, Endocrine Tumors, Other), By Region, Competition”,
has evaluated the future growth potential of Global Alpha Emitter Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Alpha Emitter Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com